微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: Alnylam’s heart drug troubles take center stage at a cardiology conference
RSS 官方收录 · 可信分层展示
关键摘要
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter.STAT+ subscribers can sign up here to get it delivered to their inbox.…
- The European Society of Cardiology Congress that kicks off Friday in M…
- Cardiologists and investors attending the ESC meeting will learn new d…
- Continue to STAT+ to read the full story…
摘要引擎：抽取
正文提要
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
The European Society of Cardiology Congress that kicks off Friday in Munich will be a consequential meeting for Alnylam Pharmaceuticals, as the outlook wavers for its two ATTR-CM drugs because of a competing drug’s surprising failure in the same heart disease.
Cardiologists and investors attending the ESC meeting will learn new details from AstraZeneca and Ionis Pharmaceuticals about why their rival drug, eplontersen, failed to significantly reduce the risk of cardiovascular deaths or recurrent events compared to a placebo.